Robert W. Baird Has Lowered Expectations for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

Karyopharm Therapeutics (NASDAQ:KPTI - Free Report) had its price target reduced by Robert W. Baird from $75.00 to $54.00 in a report released on Monday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other brokerages have also commented on KPTI. StockNews.com lowered Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Royal Bank of Canada restated an "outperform" rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. HC Wainwright increased their target price on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Remove Ads

Karyopharm Therapeutics Trading Up 1.6 %

KPTI stock traded up $0.10 during midday trading on Monday, hitting $6.22. The stock had a trading volume of 74,034 shares, compared to its average volume of 88,592. Karyopharm Therapeutics has a 52 week low of $5.90 and a 52 week high of $25.50. The stock has a 50-day simple moving average of $9.67 and a 200 day simple moving average of $11.12. The firm has a market capitalization of $52.37 million, a price-to-earnings ratio of -6.10 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. On average, equities analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $27,000. Focus Partners Wealth bought a new position in Karyopharm Therapeutics in the 4th quarter worth approximately $31,000. TD Waterhouse Canada Inc. acquired a new position in Karyopharm Therapeutics during the 4th quarter worth $32,000. Two Sigma Advisers LP boosted its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock valued at $52,000 after buying an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at $85,000. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).